POSTERS

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023

Cladribine tablets

1. Song Y, et al. Real-World Treatment Patterns and Effectiveness of Cladribine Tablets in Patients with Relapsing Forms of Multiple Sclerosis in the United States
2. Hellwig H, et al. Pregnancy and Infant Outcomes from an Ongoing Worldwide Surveillance Program of Cladribine Tablets: 5-Year Pharmacovigilance Results From MAPLE-MS
3. Wiendl H, et al. Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
4. Langdon D, et al. Stabilization of Cognitive Function in Patients with Highly Active Relapsing Multiple Sclerosis Treated with Cladribine Tablets During the 2-Year CLARIFY-MS Study
5. Selmaj K, et al. Stability of Employment Status Among Patients with Highly Active Relapsing Multiple Sclerosis During the 2-Year CLARIFY-MS Study
6. Robertson D, et al. Self-Reported Adherence and Interval Safety from the US Phase IV MASTER-2 and CLICK-MS Studies of Cladribine Tablets in Patients with Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Prior Disease-Modifying Therapy
7. Cantoni C, et al. Emergence of a Unique T Cell Population Associated with Cladribine Tablet Treatment in Multiple Sclerosis
8. Lee J, et al. Characteristics and Treatment Patterns of Patients with Multiple Sclerosis Initiating Cladribine Tablets in the United States
9. Nicholas J, et al. A Cross-Sectional Survey Evaluating Cladribine Tablets Treatment Patterns Among Patients with Multiple Sclerosis Across the US Enrolled in the MS LifeLines Patient Support Program

Evobrutinib

1. Montalban X, et al. Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension
2. Bar-Or A, et al. Immune Response Following COVID-19 Vaccination (mRNA or non-mRNA) in Patients with Relapsing Multiple Sclerosis Treated with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib: An Update
3. Kebir H, et al. The Bruton’s Tyrosine Kinase Inhibitor Evobrutinib Demonstrates Superior Efficacy in Targeting Compartmentalized Neuroinflammation Compared to Anti-CD20 Treatment
4. Kuhle J, et al. Neurofilament Light Chain Levels and Disease Activity During Long-term Treatment of Relapsing Multiple Sclerosis with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib
5. Serrano-Regal MP, et al. Evobrutinib Therapeutic Response is Associated with an Increase in the Number and Maturation of Peripheral and Central Classical Dendritic Cells

POSTERS

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022

Cladribine tablets

1. De Stefano N, et al. Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-Year MAGNIFY-MS Study
2. Solari A, et al. Improvements in Quality of Life Over 2 Years in Patients Treated with Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: Final Analysis of CLARIFY-MS
3. Giovannoni G, et al. Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Liver Safety
4. Oh J, et al. High Adherence and Minimal Delays of Year 2 Treatment in People with Multiple Sclerosis Treated with Cladribine Tablets: Results from Multi-Country Patient Support Programmes
5. Saiz A, et al. Maven4: Phase IV Non-Interventional, Prospective, Spanish Multicenter Study to Evaluate Cladribine Tablets Long-Term Effectiveness on Real-World Clinical Practice
6. Ziemssen T, et al. Treatment Emergent Adverse Events Experienced Early and Transiently in the Treatment Course with Cladribine Tablets: Data from the CLEVER Real-World Study
7. Brownlee W, et al. Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: The CLARENCE Study

Interferon beta 1-a

1. Coray M, et al. Exploring the Relationship Between Serum GDF-15 and Disease Stability in Patients with a First Clinical Demyelinating Event Treated with Subcutaneous Interferon β-1a or Placebo in the REFLEX Study
2. Arnaud L, et al. Evolution of the RebiSmart® Autoinjector Device in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for Relapsing Multiple Sclerosis

Evobrutinib

1. Bar-Or A, et al. Immune Response Following mRNA COVID-19 Vaccination in Patients with Multiple Sclerosis Treated with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib
2. Vermersch P, et al. MRI and Clinical Outcomes of Evobrutinib, A Bruton’s Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial
3. Kuhle J, et al. Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, Decreases Serum Neurofilament Light Chain Levels Over 2.5 Years of Treatment, in Patients with Relapsing Multiple Sclerosis
4. Serrano-Regal MP, et al. Evobrutinib Exerts a Therapeutic Action on EAE by Increasing the Peripheral and Central Classical Dendritic Cell Number and Maturation
5. Geladaris A, et al. Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, Acts on Microglia: Implications in the Treatment of Progressive Mechanisms In Multiple Sclerosis
6. Bogers L, et al. B Cells Infiltrating the MS Brain: From Local Maturation to Targeting by Evobrutinib

POSTERS

American Academy of Neurology (AAN) 2022

Cladribine tablets

1. Butzkueven H, et al. Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry
2. Yavorskaya V, et al. Clinical Outcomes in Patients with COVID-19 During Two Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis: An Update
3. Miravalle A, et al. Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis After Suboptimal Response to a Disease-Modifying Therapy (CLICK-MS and MASTER-2): Interim Baseline and Safety Review
4. Brownlee W, et al. Comparative Effectiveness of Cladribine Versus Fingolimod in the Treatment of Highly Active Relapsing Multiple Sclerosis: The MavEnclad Real worLd comparative efficacY non-iNterventional (MERLYN) Study
5. Nicholas J, et al. Patient Practices and Experiences During COVID-19 Among Individuals Across the United States Enrolled in MS LifeLines Patient Support Program
6. Nicholas J, et al. A Cross-Sectional Survey Evaluating Cladribine Tablets Treatment Patterns Among Patients with Multiple Sclerosis Across the US Enrolled in the MS LifeLines Patient Support Program

Interferon beta-1a

1. Freedman MS, et al. Post-approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
2. Sabidó M, et al. INFORM - Interferon Beta Exposure in the 2nd and 3rd Trimester of Pregnancy - A Register-Based Drug Utilisation Study in Finland and Sweden
3. Coray M, et al. Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon β-1a in the REFLEX Trial

Evobrutinib

1. Montalban X, et al. Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor in Relapsing Multiple Sclerosis over 2.5 Years of the Open-Label Extension to a Phase II Trial
2. Bassani C, et al. The Role of Human and Mouse BTK in Myeloid Cells

ORAL PRESENTATIONS

American Academy of Neurology (AAN) 2022

Evobrutinib

1. Arnold D, et al. Effects of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, on Slowly Expanding Lesions, an Emerging Imaging Marker of Chronic Tissue Loss in Multiple Sclerosis
2. Guehring H, et al, et al. Safety Profile Characterization of Evobrutinib in Over 1000 Patients from Phase II Clinical Trials in Multiple Sclerosis, Rheumatoid Arthritis and Systemic Lupus Erythematosus

POSTERS

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2022

Cladribine tablets

1. Butzkueven H, et al. Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry
2. Leist T, et al. Primary Results from 8-11 Years of Follow-Up in the CLASSIC-MS Study Show Long-Term Efficacy for Patients Who Received Cladribine Tablets in ORACLE MS
3. Nicholas J, et al. A Cross-Sectional Survey Evaluating Cladribine Tablets Treatment Patterns Among Patients with Multiple Sclerosis Across the US Enrolled in the MS LifeLines Patient Support Program
4. Brownlee W, et al. Comparative Effectiveness of Cladribine Versus Fingolimod in the Treatment of Highly Active Relapsing Multiple Sclerosis: The MavEnclad Real worLd comparative efficacY non-iNterventional (MERLYN) Study
5. Giovannoni G, et al. Post-Approval Safety of Cladribine Tablets with Particular Reference to COVID-19 Outcomes: An Update

Evobrutinib

1. Zalc B, et al. Evobrutinib Promotes Myelin Regeneration in Two Different Models of Demyelination*

Other

1. Freeman L, et al. Preventive Care Among Older People with Multiple Sclerosis
2. Kuranz S, et al. Rates of Multiple Sclerosis Relapse, Severe Relapse, and Health Care Resource Utilization Following COVID-19 Vaccination: Real-World Evidence from a US EMR Network
3. Loonstra FC, et al. Serum Adipokine Levels in Multiple Sclerosis Patients of the Same Age and Their Association with Clinical and Radiological Measures

POSTERS

Consortium of Multiple Sclerosis Centers (CMSC) 2021

Cladribine tablets

1. Karan R, et al. Clinical Outcomes in Patients with COVID-19 Infection During Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis
2. Giovannoni G, et al. Post-Approval Safety of Cladribine Tablets with Particular Reference to COVID-19 Outcomes: An Update
3. Wiendl H, et al. Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study
4. Giovannoni G, et al. Long-Term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-Up in the CLASSIC-MS Study
5. Miravalle A, et al. CLICK-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis After Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)

Interferon beta-1a

1. Freedman M, et al. Post-Approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections

Evobrutinib

1. Kuhle J, et al. The Effect of Evobrutinib, a BTK Inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis
2. Piasecka-Stryczynska K, et al. Concentration of Evobrutinib, a BTK Inhibitor, in Cerebrospinal Fluid During Treatment of Patients with Relapsing Multiple Sclerosis in a Phase II Study
3. Montalban X, et al. Evobrutinib Efficacy is Maintained Over Two years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis
4. Montalban X, et al. Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Other

1. Bove R, et al. Comparing Infection-Related Outcomes by Sex in Patients with Multiple Sclerosis and Matched Controls Using Administrative Claims Data
2. Hendin B, et al. Clinical and Economic Burden of Employees Who Are Care Partners of Patients with Multiple Sclerosis
3. Hendin B, et al. Assessing Presence of MS-Related Symptoms as a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data
4. Nicholas J, et al. Patient Practices and Experiences During COVID-19 Among Individuals Across the United States Enrolled in MS LifeLines Patient Support Program
5. Col N, et al. Patient-Provider Communication about Multiple Sclerosis: The MS-SUPPORT Decision Aid

ORAL PRESENTATION

Consortium of Multiple Sclerosis Centers (CMSC) 2021

Other

1. Hellwig K, et al. Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease Modifying Drugs: A Systematic Review

POSTERS

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2021

Cladribine tablets

1. Giovannoni G, et al. Post-Approval Safety of Cladribine Tablets with Particular Reference to COVID-19 Outcomes: An Update
2. Giovannoni G, et al. Long-term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-up in the CLASSIC-MS Study
3. Butzkueven H, et al. Real-world Experience with Cladribine in the MSBase Registry
4. Sguigna P, et al. Cladribine Tablets after Treatment with Natalizumab (CLADRINA) Trial – Interim Analyses
5. Fox EJ, et al. MASTER-2 Trial: Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis after Suboptimal Response to Prior Infusion/Oral Disease-Modifying Therapy (Interim Baseline Results)
6. Hellwig K, et al. A Multi-Country Cohort Database Study to Assess Pregnancy and Infant Outcomes in Women Exposed to Cladribine Tablets: CLEAR Study
7. Solari A, et al. Improvements in QoL at 1 Year in Patients Treated with Cladribine Tablets for Highly Active Relapsing MS: An Interim Analysis of CLARIFY-MS
8. Hillert J, et al. Incidence of Infections and Severe Lymphopenia in Patients Newly Initiating Cladribine Tablets or Fingolimod for Treatment of Multiple Sclerosis: CLARION Study
9. Butzkueven H, et al. Disease-Modifying Treatment Patterns of Patients With Multiple Sclerosis and Newly Treated With Cladribine Tablets or Fingolimod: An Interim Analysis of the CLARION Study
10. Oh J, et al. High Adherence to Treatment with Cladribine Tablets for Multiple Sclerosis During the COVID-19 Pandemic: Results From Patient Support Programmes

Interferon beta-1a

1. Sabido M, et al. Interferon Beta Exposure in the 2nd and 3rd Trimester of Pregnancy - A Register-Based Drug Utilisation Study in Finland and Sweden
2. Coray M, et al. Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon β-1a in the REFLEX Trial
3. Gentile G, et al. Development and Interrelation of Spatiotemporal Patterns of Brain Atrophy and Lesions During 5 Years’ Treatment with Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study
4. Mattiesing RM, et al. Development and Interrelation of Whole-Brain Atrophy and Lesion Volume During 5 Years’ Treatment with Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study
5. DiCillo EB, et al. Genome-Wide Mapping of Patient Autoantibody Targets to Understand and Predict Multiple Sclerosis Pathogenesis and Patient Responses to Interferon Beta-1a Therapy

Evobrutinib

1. Montalban X, et al. Safety Profile Characterization of Evobrutinib in Over 1000 Patients from Phase II Clinical Trials in Multiple Sclerosis, Rheumatoid Arthritis and Systemic Lupus Erythematosus
2. Bassani C, et al. The Role of Human and Mouse BTK in Myeloid Cells
3. Geladaris A, et al. Targeting BTK in Chronic CNS Autoimmunity Inhibits Activation of Microglia

Other

1. Bouman P, et al. Towards a New Resource for the MS Brain: A Cross Brain Bank Proteomic Atlas of Non Lesional Neocortex
2. Engebretson E, et al. DISCOntinuation of Disease Modifying therapies in MS (DISCOMS) Extension Study Design and Baseline Demographics
3. Bosco-Levy P, et al. Risk of Cancer with Disease-Modifying Therapies in Multiple Sclerosis: A New-User Cohort Design in the French Nationwide Claims Database

ORAL PRESENTATIONS

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2021

Evobrutinib

1. Kuhle J, et al. Evobrutinib Significantly Reduces Relapses and Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis: Association with Baseline Neurofilament Light Chain Levels
2. Arnold D, et al. Effects of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Slowly Expanding Lesions: An Emerging Imaging Marker of Chronic Tissue Loss in Multiple Sclerosis

ORAL PRESENTATIONS

American Academy of Neurology (AAN) 2021

Cladribine tablets

1. Wiendl H, et al. Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study

Evobrutinib

1. Rijvers L, et al. Human T-bet+ B-cell Development: Association with Bruton’s Tyrosine Kinase and Targeting by Evobrutinib

POSTERS

American Academy of Neurology (AAN) 2021

Cladribine tablets

1. Giovannoni G, et al. Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19
2. Giovannoni G, et al. CLASSIC-MS: Long-term Efficacy and Real-World Treatment Patterns for Patients who Received Cladribine Tablets in Phase III Parent Trials
3. De Stefano N, et al. Reduction in CUA MRI Lesions in the First 6 Months after Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Subgroup Analysis
4. Battaglini M, et al. Reduced Grey Matter Atrophy in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets
5. Brochet B, et al. Treatment Satisfaction in Patients with Highly-active Relapsing Multiple Sclerosis Treated with Cladribine Tablets: CLARIFY-MS Study Interim Analysis

Interferon beta-1a

1. Freedman MS, et al. Post-approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
2. Kuhle J, et al. Investigating the Correlation between Serum Neurofilament Light Chain (sNfL) Concentration and Magnetic Resonance Imaging (MRI)-Outcomes in Patients with a First Clinical Demyelinating Event in the REFLEX trial
3. Kuhle J, et al. Baseline Serum Neurofilament Light Chain Levels Predict Conversion to McDonald 2005 Multiple Sclerosis (MS) Within 2 Years of a First Clinical Demyelinating Event in Patients with MS

Evobrutinib

1. Kuhle J, et al. The Effect of Evobrutinib, a BTK inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis
2. Montalban X, et al. Evobrutinib Efficacy is Maintained over Two Years in an Open-label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis
3. Montalban X, et al. Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis is Maintained in a Long-Term Open-label Extension of a Phase II Study
4. Kebir H, et al. Expression of BTK in Leptomeningeal B-cell Rich Infiltrates in Two Models of Progressive Multiple Sclerosis and its Inhibition by Evobrutinib Underscores BTK as a Target for Compartmentalized Neuroinflammation

Other

1. Hellwig K, et al. Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease-Modifying Therapy: A Systematic Review
2. Hendin B, et al. Assessing Presence of MS-related Symptoms as a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data

POSTERS

Americas Committee for Treatment and Research in Multiple Sclerosis 2020

1. Effectiveness of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis with Baseline EDSS ≥3.5 or ≤3.0 in CLARITY
2. Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Post-approval Data
3. Increased Naïve B Cells, M2 Macrophages, and Decreased Memory B and T Cells during Immune Repopulation in CLARITY Assessed by Immune Cell Deconvolution
4. Efficacy of Cladribine Tablets on Individual Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis Not Achieving NEDA Status in CLARITY
5. Cladribine Tablets in Patients with Relapsing Forms of Multiple Sclerosis Who Had Suboptimal Response to Injectable Disease-Modifying Drug (CLICK-MS)
6. Cladribine Tablets Demonstrate Similar Efficacy in Male and Female Patients with Relapsing-Remitting Multiple Sclerosis in CLARITY
7. The CLARITY Study: Efficacy Outcomes Among Patients who Received Disease-Modifying Drugs Prior to Treatment with Cladribine Tablets
8. Reduction of Risk of Secondary Progressive Multiple Sclerosis Within Two Years of Treatment with Cladribine Tablets: An Analysis of the CLARITY Study
9. Time to First Relapse over the Duration of CLARITY and CLARITY Extension in Patients Treated with Cladribine Tablets Only during CLARITY
10. Efficacy Outcomes in Cladribine Tablets-Treated Patients in CLARITY were Similar between Patients Who Did Versus Did Not Enter CLARITY Extension
11. Post Hoc Analysis to Evaluate the Effects of Subcutaneous Interferon Beta-1a in Subgroups of Patients from the PRISMS Study with Early-Onset Versus Late-Onset Disease
12. Effect of Interferon β-1a Treatment on Serum Neurofilament Light-Chain Levels in Patients with a First Clinical Demyelinating Event in the REFLEX Trial
13. Effect of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Immune Cell and Immunoglobulin Levels Over 48 Weeks in a Phase 2 Study in Relapsing Multiple Sclerosis
14. Suboptimal Treatment Outcomes in Employees with Multiple Sclerosis Initiating Disease-Modifying Drugs

POSTERS

American Academy of Neurology 2020

1. Long-term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies
2. Reduction of Risk of Secondary Progressive Multiple Sclerosis Within Two Years of Treatment with Cladribine Tablets: An Analysis of the CLARITY Study
3. Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Post-approval Data
4. Long-term Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting or Secondary Progressive Multiple Sclerosis: Analysis of Real-World Data From the Italian Multiple Sclerosis Registry (CLARINET-MS)
5. Expert Opinion on the Use of Cladribine Tablets in Clinical Practice
6. Cladribine Decreases CD95-expressing CD4⁺ and CD8⁺ Cells in Lymphoid Organs in Naïve Marmosets (Callithrix jacchus)
7. Year 1 Performance of adveva®, a Patient Support Program for Patients Taking Cladribine Tablets for Highly Active Relapsing Remitting Multiple Sclerosis in the United Kingdom
8. Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine-treated Patients at the 96-week Timepoint (CLARITY) Using Deconvolution Algorithms

POSTERS

Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) / European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting 2020

1. Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
2. CLASSIC-MS: Long term Efficacy and Real-World Treatment Patterns for Patients Receiving Cladribine Tablets - Interim Data with 8-14 Years’ Follow-up
3. Durable Efficacy of Cladribine Tablets: Cumulative Relapse Incidence Over 5 Years in CLARITY and CLARITY Extension
4. Reduction in CUA MRI Lesions in the First 6 Months of Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Study
5. Clinical Outcomes in Patients with COVID-19 Infection During Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis
6. Reduced Grey Matter Atrophy in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets
7. Treatment-Emergent Adverse Events Occurring Early in the Treatment Course of Cladribine Tablets in Two Phase 3 Trials in Multiple Sclerosis
8. Evaluation of Disability Improvement in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Cladribine Tablets as Measured by the Expanded Disability Status Scale Score
9. Cladribine Tablets in Patients with RRMS and Active SPMS After Suboptimal Response to Prior DMD (MASTER-2 and CLICK-MS): Initial Baseline Demographics
10. MS Disease Modifying Therapy Sequencing – Natalizumab to Cladribine Tablets – Experience in 50 Patients
11. The Interpretation and Clinical Application of the PROMIS® SF v1.0 - Fatigue (MS) 8b: A PROMIS Short Form for Assessing Fatigue in Multiple Sclerosis
12. The Validity and Applicability of a New PROMIS® Physical Function Short Form for Use in Relapsing and Progressive Multiple Sclerosis
13. Age-Related Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting MS in the CLARITY Extension Study
14. Clinical Relapse Rates in Relapsing MS Patients Treated with the BTK Inhibitor Evobrutinib: Results of an Open-label Extension to a Phase II Study
15. Real-World Experience with Cladribine Tablets in the MSBase Registry
16. Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib in Relapsing Multiple Sclerosis During an Open-Label Extension to a Phase II Study
17. Treatment and Care Management, Clinical Outcomes and Mobility Impairment in People with or Without MS Aged ≥ 50 Years: Observational 6-Year Analysis
18. Treatment Satisfaction in Patients with Highly-Active Relapsing Multiple Sclerosis Treated with Cladribine Tablets: CLARIFY-MS Study Interim Analysis
19. Effects of Cladribine on Proliferation, Survival and Cytokine Release of Human Astrocytes
20. Evobrutinib, a Highly Selective BTK Inhibitor, Prevents Antigen-Activation of B Cells and Ameliorates Experimental Autoimmune Encephalomyelitis
21. Low Discontinuation Rate and Side-Effect Burden After Switching to Cladribine Tablets: Canadian Experience from the adveva® Patient Support Program
22. Effect of Evobrutinib, a BTK Inhibitor, on Immune Cell and Immunoglobulin Levels in Relapsing MS: an Open-Label Extension to a Phase II Study
23. CLADQoL (CLADribineTablets – Evaluation of Quality of Life) Study: Evaluating QoL12 Months after Treatment Initiation with Cladribine Tablets
24. The Bruton’s Tyrosine Kinase Inhibitor Evobrutinib Ameliorates Meningeal Inflammation in Experimental Autoimmune Encephalomyelitis
25. Effect of Neutralizing Antibodies on Pharmacodynamic Biomarkers of Subcutaneous Interferon β-1a in REFLEX and REFLEXION
26. Baseline Serum Neurofilament Light Chain Levels Predict Conversion to McDonald 2005 MS Within 2 Years of a First Clinical Demyelinating Event in REFLEX
27. Effect of Age on Effectiveness and Discontinuation of Subcutaneous Interferon β-1a, and Healthcare Utilization, in Patients with Multiple Sclerosis
28. Characteristics of Relapsing Multiple Sclerosis Patients Treated with Cladribine Tablets in Five European Countries: An Analysis of Multi-Year Chart Review Data
29. Cladribine Tablets Versus Other Highly Active Disease-Modifying Therapies in Multiple Sclerosis in Achieving Sustained Disability Improvement (SDI) Network Meta-Analysis
30. Expression of Bruton’s Tyrosine Kinase (BTK) in B Cell-Rich Meningeal Infiltrates in Two Models of Progressive MS
31. T-Bet⁺ B-Cell Development in MS: Association with Bruton’s Tyrosine Kinase Activity and Targeting by Evobrutinib

POSTERS

Consortium of Multiple Sclerosis Centers Meeting 2020

1. Rationale and Design of Classic-MS Study Evaluating Long-Term Efficacy for Patients with Multiple Sclerosis Treated with Cladribine Tablets
2. Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine-Treated Patients at the 96-week Timepoint (CLARITY) Using Deconvolution Algorithms
3. Post Hoc Analysis of Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Diagnosed Within 3 or 4 Years Prior to the CLARITY Study
4. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies
5. Integrated Lymphopenia Analysis in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets
6. Effectiveness of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis with Baseline EDSS ≥3.5 or ≤3.0 in CLARITY
7. Post Hoc Analysis of Efficacy of Cladribine Tablets in Patients with Relapsing Remitting Multiple Sclerosis Aged Over and Under 30 Years in the CLARITY Study
8. Reduction of Risk of Secondary Progressive Multiple Sclerosis Within Two Years of Treatment with Cladribine Tablets: An Analysis of the CLARITY Study
9. The CLARITY Study: Efficacy Outcomes Among Patients who Received Disease-Modifying Drugs Prior to Treatment with Cladribine Tablets
10. Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Post-approval Data
11. An Analysis of the Relationship Between Cladribine Dose and Risk of Malignancies in Patients with Multiple Sclerosis
12. Efficacy of Subcutaneous Interferon β-1a in Patients with a First Clinical Demyelinating Event: REFLEX Study – Outcomes in Patients Stratified by 2017 McDonald Criteria
13. Prevalence of Serious Adverse Pregnancy Outcomes After Exposure to Interferon Beta Before or During Pregnancy: Stratification by Characteristics of Pregnant Women with MS in a Register-Based Cohort Study in Finland and Sweden
14. Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib In Relapsing Multiple Sclerosis over 108 Weeks: Open-Label Extension to a Phase 2 Study
15. Effect of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Immune Cell and Immunoglobulin Levels over 48 Weeks in a Phase 2 Study in Relapsing Multiple Sclerosis
16. Real-World Patterns of Outcomes in Patients with Multiple Sclerosis Who Are Adherent versus Non-Adherent to Disease Modifying Treatments over 6 Years
17. The Implications of Suboptimal Treatment Outcomes with Disease-Modifying Drugs in Employees with Multiple Sclerosis

POSTERS

Americas Committee for Treatment and Research in Multiple Sclerosis 2021

Cladribine tablets

1. Roy S, et al. Analysis of Influenza and Varicella Zoster Virus Vaccine Antibody Titers in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets​
2. Wu GF, et al. Evaluating the Impact of Cladribine Tablets on the Development of Antibody Titers: Interim Results from the CLOCK-MS Influenza Vaccine Substudy​
3. Coyle PK, et al. Analysis of Infection in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets Who Had Grade ≥3 Lymphopenia​
4. Giovannoni G, et al. Analysis of Lymphocyte Subsets in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets
5. Okai A, et al. The CLADRINA Trial: Evaluating Treatment with Cladribine Tablets Following Natalizumab ​​

Other

1. Bove R, et al. Risk of Specific Infections in Patients with Multiple Sclerosis Versus Matched Controls: An Analysis of Administrative Claims Data
2. Cisternas MG, et al. Longitudinal Adherence Trajectories of Patients with Multiple Sclerosis Initiating Once- or Twice-Daily Oral Disease-Modifying Therapies​

PUBLICATIONS

Cladribine tablets

Pivotal Trials

1. Giovannoni G, et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. N Engl J Med 2010; 362: 416-26.
2. Giovannoni G, et al. Safety and Efficacy of Cladribine Tablets in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized Extension Trial of the CLARITY Study. Multiple Sclerosis Journal 2018, Vol. 24(12) 1594 –1604.

Vaccinations

1. Achiron A, et al. Humoral Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Treated with High-Efficacy Disease-Modifying Therapies. Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835.
2. Achiron A, et al. COVID-19 Vaccination in Patients with Multiple Sclerosis: What We Have Learnt by February 2021. Mult Scler. 2021 May;27(6):864-870.
3. Brill L, et al. Effect of Cladribine on COVID-19 Serology Responses Following Two Doses of the BNT162b2 mRNA Vaccine in Patients with Multiple Sclerosis. Mult Scler Relat Disord. 2021 Oct 23:103343.

Mechanism of Action

1. Comi G, et al. Effect of Cladribine Tablets on Lymphocyte Reduction and Repopulation Dynamics in Patients with Relapsing Multiple Sclerosis. Mult Scler Relat Disord. 2019 Apr;29:168-174.
2. Rammohan K, et al. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review. Drugs. 2020 Dec;80(18):1901-1928.
3. Stuve O, et al. Effects of Cladribine Tablets on Lymphocyte Subsets in Patients with Multiple Sclerosis: An Extended Analysis of Surface Markers. Ther Adv Neurol Disord. 2019 Jun 18;12:1756286419854986.

Long-term Safety

1. Leist T, et al. Long-Term Safety Data from the Cladribine Tablets Clinical Development Program in Multiple Sclerosis. Mult Scler Relat Disord. 2020 Nov;46:102572.

PUBLICATIONS

Interferon beta-1a

Pivotal Trials

1. Li DK, et al. Magnetic Resonance Imaging Results of the PRISMS Trial: A Randomized, Double-Blind, Placebo-Controlled Study of Interferon-Beta1a in Relapsing-Remitting Multiple Sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol. 1999 Aug;46(2):197-206.
2. Panitch H, et al. EVidence of Interferon Dose-Response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, Comparative Study of Interferon Beta-1a Treatment Regimens in MS: The EVIDENCE Trial. Neurology. 2002 Nov 26;59(10):1496-506.
3. PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised Double-Blind Placebo-Controlled Study of Interferon Beta-1a in Relapsing/Remitting Multiple Sclerosis. Lancet. 1998 Nov 7;352(9139):1498-504.

Vaccinations

1. Schwid SR, et al. Immune Response to Influenza Vaccine is Maintained in Patients with Multiple Sclerosis Receiving Interferon Beta-1a. Neurology. 2005 Dec 27;65(12):1964-6.

Pregnancy and Lactation

1. Burkill S, et al. The Association Between Exposure to Interferon-Beta During Pregnancy and Birth Measurements in Offspring of Women with Multiple Sclerosis. PLoS One. 2019 Dec 30;14(12):e0227120.
2. Hakkarainen KM, et al. Pregnancy Outcomes after Exposure to Interferon Beta: A Register-Based Cohort Study Among Women with MS in Finland and Sweden. Ther Adv Neurol Disord. 2020 Oct 7;13:1756286420951072.
3. Hale TW, et al. Transfer of Interferon β-1a into Human Breastmilk. Breastfeed Med. 2012 Apr;7(2):123-5.

Long-term Outcomes

1. Kappos L, et al. Factors Influencing Long-Term Outcomes in Relapsing-Remitting Multiple Sclerosis: PRISMS-15. J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1202-7.

Real-World Evidence

1. Allignol A, et al. Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database. Front Neurol. 2021 Jul 22;12:676585.

PUBLICATIONS

Evobrutinib

Preclinical Trials

1. Bhargava P, et al. Imaging Meningeal Inflammation in CNS Autoimmunity Identifies a Therapeutic Role for BTK Inhibition. Brain. Jun 22 2021;144(5):1396-1408.
2. Caldwell RD, et al. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019;62(17):7643-7655.
3. Haselmayer P, et al. Efficacy and Pharmacodynamic Modeling of the BTK inhibitor Evobrutinib in Autoimmune Disease Models. J Immunol. 2019;202(10):2888-2906.
4. Martin E, et al. Bruton's Tyrosine Kinase Inhibition Promotes Myelin Repair. Brain Plast. 2020;5(2):123-133.
5. Torke S, et al. Inhibition of Bruton's Tyrosine Kinase Interferes with Pathogenic B-cell Development in Inflammatory CNS Demyelinating Disease. Acta Neuropathol. 2020;140(4):535-548.

Clinical Trials

1. Becker A, et al. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers. Clin Transl Sci. 2020;13(2):325-336.
2. Kuhle J, et al. The Effect of Evobrutinib, a BTK Inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis. Neurology. 2021;96(22):e2783-88.
3. Montalban X, et al. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. N Engl J Med. 2019;380(25):2406-17.

Upcoming Programs

• Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI, March 28, 2023

POSTERS

Consortium of Multiple Sclerosis Centers (CMSC) 2022

Cladribine tablets

1. Giovannoni G, et al. Long-Term Efficacy for Patients Receiving Cladribine Tablets (3.5 mg/kg over 2 Years) in CLARITY/CLARITY Extension: A Post Hoc Analysis of CLASSIC-MS
2. Wu G, et al. CLadribine Tablets: Collaborative Study to Evaluate the Impact On CNS BiomarKers in Multiple Sclerosis (CLOCK-MS) – Current Baseline Characteristics
3. Sguigna P, et al. Cladribine Tablets After Treatment with Natalizumab (CLADRINA) Trial - Interim Analyses

Interferon beta-1a

1. Freedman M, et al. Post-Approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
2. Coray M, et al. Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon β-1a in the REFLEX Trial
3. Gentile G, et al. Development and Interrelation of Spatiotemporal Patterns of Brain Atrophy and Lesions During 5 Years’ Treatment with Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study
4. Mattiesing R, et al. Development and Interrelation of Whole-Brain Atrophy and Lesion Volume During 5 Years’ Treatment with Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study

Evobrutinib

1. Arnold D, et al. Effects of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, on Slowly Expanding Lesions: An Emerging Imaging Marker of Chronic Tissue Loss in Multiple Sclerosis
2. Kuhle J, et al. Evobrutinib Significantly Reduces Relapses and Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis: Association with Baseline Neurofilament Light Chain Levels

Other

1. Col N, et al. Can a Shared Decision-Making Tool Improve Multiple Sclerosis DMT Utilization? The MS-SUPPORT Decision Aid
2. Kozma C, et al. Patient Characteristics and Treatment Patterns Prior to Initiating Cladribine Tablets: a US Retrospective Commercial Claims Analysis
3. Nicholas J, et al. Quality of Life and Treatment Outcomes Among People with Multiple Sclerosis Before and During the COVID-19 Pandemic
4. Nicholas J, et al. Work Productivity Among People with Multiple Sclerosis Before and During the COVID-19 Pandemic

ORAL PRESENTATIONS

Consortium of Multiple Sclerosis Centers (CMSC) 2022

Evobrutinib

1. Montalban X, et al. Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis over 2.5 years of the Open-Label Extension to a Phase II Trial